Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personalized oncology in interventional radiology.
Abi-Jaoudeh N, Duffy AG, Greten TF, Kohn EC, Clark TW, Wood BJ. Abi-Jaoudeh N, et al. Among authors: kohn ec. J Vasc Interv Radiol. 2013 Aug;24(8):1083-92; quiz 1093. doi: 10.1016/j.jvir.2013.04.019. J Vasc Interv Radiol. 2013. PMID: 23885909 Free PMC article. Review.
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC. Lee JM, et al. Among authors: kohn ec. J Natl Cancer Inst. 2014 May 19;106(6):dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun. J Natl Cancer Inst. 2014. PMID: 24842883 Free PMC article. Clinical Trial.
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC. Annunziata CM, et al. Among authors: kohn ec. Clin Cancer Res. 2010 Jan 15;16(2):664-72. doi: 10.1158/1078-0432.CCR-09-2308. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068097 Free PMC article. Clinical Trial.
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC. Lee JM, et al. Among authors: kohn ec. Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108297 Free PMC article.
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC. Azad N, et al. Among authors: kohn ec. Mol Cell Proteomics. 2013 Jun;12(6):1621-31. doi: 10.1074/mcp.M112.026427. Epub 2013 Feb 28. Mol Cell Proteomics. 2013. PMID: 23449826 Free PMC article. Clinical Trial.
Proteomics and biomarkers in clinical trials for drug development.
Lee JM, Han JJ, Altwerger G, Kohn EC. Lee JM, et al. Among authors: kohn ec. J Proteomics. 2011 Nov 18;74(12):2632-41. doi: 10.1016/j.jprot.2011.04.023. Epub 2011 May 4. J Proteomics. 2011. PMID: 21570499 Free PMC article. Review.
285 results